Short alleles of both GGN and CAG repeats at the exon-1 of the androgen receptor gene are associated to increased PSA staining and a higher Gleason score in human prostatic cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 113, Issue 1-2, 2009, Pages 85-91

  Rodríguez González, Germán ^a,b   Cabrera, Saúl ^a   Ramírez Moreno, Raquel ^a   Bilbao, Cristina ^a   Díaz Chico, Juan C ^a,b   Serra, Lluis ^a,b   Chesa, Nicolás ^a,c   Cabrera, Juan J ^a,b,d   Díaz Chico, B Nicolás ^a,b  

^a Madrid Spain   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^c UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^d HOSPITAL UNIVERSITARIO MATERNO INFANTIL DE CANARIAS   (Spain)

Author keywords

GGN repeat and androgen receptor; Immunohistochemistry; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN RECEPTOR; GLYCINE; POLYGLUTAMINE; POLYGLYCINE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROSTATECTOMY;

AGED; ALLELES; CASE-CONTROL STUDIES; EXONS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STAINING AND LABELING; STATISTICS, NONPARAMETRIC; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 59849115545     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.11.010     Document Type: Article

References (52)

1. Buchanan G., Irvine R.A., Coetzee G.A., and Tilley W.D. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev. 20 3-4 (2001) 207-223
2. Navarro D., Luzardo O.P., Fernandez L., Chesa N., and Diaz-Chico B.N. Transition to androgen-independence in prostate cancer. J. Steroid Biochem. Mol. Biol. 81 3 (2002) 191-201
3. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23 32 (2005) 8253-8261
4. Culig Z., Steiner H., Bartsch G., and Hobisch A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr. Relat. Cancer 12 2 (2005) 229-244
5. Brinkmann A.O., Faber P.W., van Rooij H.C., Kuiper G.G., Ris C., Klaassen P., van der Korput J.A., Voorhorst M.M., van Laar J.H., Mulder E., et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J. Steroid Biochem. 34 1-6 (1989) 307-310
6. Jenster G., van der Korput H.A., Trapman J., and Brinkmann A.O. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. 270 13 (1995) 7341-7346
7. Chamberlain N.L., Driver E.D., and Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 22 15 (1994) 3181-3186
8. Beilin J., Ball E.M., Favaloro J.M., and Zajac J.D. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J. Mol. Endocrinol. 25 1 (2000) 85-96
9. Ding D., Xu L., Menon M., Reddy G.P., and Barrack E.R. Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate 58 1 (2004) 23-32
10. Irvine R.A., Yu M.C., Ross R.K., and Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 55 9 (1995) 1937-1940
11. Hakimi J.M., Schoenberg M.P., Rondinelli R.H., Piantadosi S., and Barrack E.R. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin. Cancer Res. 3 9 (1997) 1599-1608
12. Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., Talcott J., Hennekens C.H., and Kantoff P.W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. U.S.A. 94 7 (1997) 3320-3323
13. Ingles S.A., Ross R.K., Yu M.C., Irvine R.A., La Pera G., Haile R.W., and Coetzee G.A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. 89 2 (1997) 166-170
14. Stanford J.L., Just J.J., Gibbs M., Wicklund K.G., Neal C.L., Blumenstein B.A., and Ostrander E.A. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 57 6 (1997) 1194-1198
15. Miller E.A., Stanford J.L., Hsu L., Noonan E., and Ostrander E.A. Polymorphic repeats in the androgen receptor gene in high-risk sibships. Prostate 48 3 (2001) 200-205
16. Platz E.A., Leitzmann M.F., Rifai N., Kantoff P.W., Chen Y.C., Stampfer M.J., Willett W.C., and Giovannucci E. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol. Biomarkers Prev. 14 5 (2005) 1262-1269
17. Yu H., Bharaj B., Vassilikos E.J., Giai M., and Diamandis E.P. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res. Treat. 59 2 (2000) 153-161
18. Levine D.A., and Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res. 61 3 (2001) 908-911
19. Rodriguez G., Bilbao C., Ramirez R., Falcon O., Leon L., Chirino R., Falcon Jr. O., Diaz B.P., Rivero J.F., Perucho M., Diaz-Chico B.N., and Diaz-Chico J.C. Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. Int. J. Cancer 118 6 (2006) 1420-1425
20. Hardy D.O., Scher H.I., Bogenreider T., Sabbatini P., Zhang Z.F., Nanus D.M., and Catterall J.F. Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J. Clin. Endocrinol. Metab. 81 12 (1996) 4400-4405
21. Freedman M.L., Pearce C.L., Penney K.L., Hirschhorn J.N., Kolonel L.N., Henderson B.E., and Altshuler D. Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am. J. Hum. Genet. 76 1 (2005) 82-90
22. Edwards S.M., Badzioch M.D., Minter R., Hamoudi R., Collins N., Ardern-Jones A., Dowe A., Osborne S., Kelly J., Shearer R., Easton D.F., Saunders G.F., Dearnaley D.P., and Eeles R.A. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int. J. Cancer 84 5 (1999) 458-465
23. Nam R.K., Elhaji Y., Krahn M.D., Hakimi J., Ho M., Chu W., Sweet J., Trachtenberg J., Jewett M.A., and Narod S.A. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J. Urol. 164 2 (2000) 567-572
24. Bratt O., Borg A., Kristoffersson U., Lundgren R., Zhang Q.X., and Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br. J. Cancer 81 4 (1999) 672-676
25. Nelson K.A., and Witte J.S. Androgen receptor CAG repeats and prostate cancer. Am. J. Epidemiol. 155 10 (2002) 883-890
26. Sleddens H.F., Oostra B.A., Brinkmann A.O., and Trapman J. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum. Mol. Genet. 2 4 (1993) 493
27. Ding D., Xu L., Menon M., Reddy G.P., and Barrack E.R. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate 62 2 (2005) 133-139
28. Platz E.A., Giovannucci E., Dahl D.M., Krithivas K., Hennekens C.H., Brown M., Stampfer M.J., and Kantoff P.W. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 7 5 (1998) 379-384
29. Hsing A.W., Gao Y.T., Wu G., Wang X., Deng J., Chen Y.L., Sesterhenn I.A., Mostofi F.K., Benichou J., and Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 60 18 (2000) 5111-5116
30. Zeegers M.P., Kiemeney L.A., Nieder A.M., and Ostrer H. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?. Cancer Epidemiol. Biomarkers Prev. 13 11 Pt. 1 (2004) 1765-1771
31. Salinas C.A., Austin M.A., Ostrander E.O., and Stanford J.L. Polymorphisms in the androgen receptor and the prostate-specific antigen genes and prostate cancer risk. Prostate 65 1 (2005) 58-65
32. Forrest M.S., Edwards S.M., Houlston R., Kote-Jarai Z., Key T., Allen N., Knowles M.A., Turner F., Ardern-Jones A., Murkin A., Williams S., Oram R., Bishop D.T., and Eeles R.A. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis. 8 1 (2005) 95-102
33. Correa-Cerro L., Wohr G., Haussler J., Berthon P., Drelon E., Mangin P., Fournier G., Cussenot O., Kraus P., Just W., Paiss T., Cantu J.M., and Vogel W. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur. J. Hum. Genet. 7 3 (1999) 357-362
34. Chang B.L., Zheng S.L., Hawkins G.A., Isaacs S.D., Wiley K.E., Turner A., Carpten J.D., Bleecker E.R., Walsh P.C., Trent J.M., Meyers D.A., Isaacs W.B., and Xu J. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum. Genet. 110 2 (2002) 122-129
35. Strom S.S., Gu Y., Zhang H., Troncoso P., Babaian R.J., Pettaway C.A., Shete S., Spitz M.R., and Logothetis C.J. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 60 4 (2004) 343-351
36. Montgomery J.S., Price D.K., and Figg W.D. The androgen receptor gene and its influence on the development and progression of prostate cancer. J. Pathol. 195 2 (2001) 138-146
37. Li R., Wheeler T., Dai H., Frolov A., Thompson T., and Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am. J. Surg. Pathol. 28 7 (2004) 928-934
38. Soloway M., and Roach III M. Prostate cancer progression after therapy of primary curative intent: a review of data from prostate-specific antigen era. Cancer 104 11 (2005) 2310-2322
39. Kim J., and Coetzee G.A. Prostate specific antigen gene regulation by androgen receptor. J. Cell Biochem. 93 2 (2004) 233-241
40. Boorman D.W., Guo Y., Visvanathan K., Helzlsouer K., and O'Brien T.G. Automated fragment analysis method for determining androgen receptor CAG repeat length. Biotechniques 33 1 (2002) 140-143
41. Delmotte F., Leterme N., and Simon J.C. Microsatellite allele sizing: difference between automated capillary electrophoresis and manual technique. Biotechniques 31 4 (2001) 810, 814-816, 818
42. Henriquez Sanchez P., Diaz Romero C., Rodriguez Rodriguez E., Lopez Blanco F., Alvarez Leon E., Diaz Cremades J., Pastor Ferrer M.C., and Serra Majem L. Biochemical assessment of nutritional status in the Canary Islands population (1998). Arch. Latinoam. Nutr. 50 1 Suppl. 1 (2000) 43-54
43. Serra Majem L., Armas A., and Ribas Barba NavarroL. Food consumption and food sources of energy and nutrients in Canary Islands (1997-98). Arch. Latinoam. Nutr. 50 1 Suppl. 1 (2000) 23-33
44. Serra Majem L., Ribas Barba L., Armas Navarro A., Alvarez Leon E., and Sierra A. Energy and nutrient intake and risk of inadequate intakes in Canary Islands (1997-98). Arch. Latinoam. Nutr. 50 1 Suppl. 1 (2000) 7-22
45. Ricciardelli C., Choong C.S., Buchanan G., Vivekanandan S., Neufing P., Stahl J., Marshall V.R., Horsfall D.J., and Tilley W.D. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 63 1 (2005) 19-28
46. Boddy J.L., Fox S.B., Han C., Campo L., Turley H., Kanga S., Malone P.R., and Harris A.L. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin. Cancer Res. 11 21 (2005) 7658-7663
47. Ayala G., Tuxhorn J.A., Wheeler T.M., Frolov A., Scardino P.T., Ohori M., Wheeler M., Spitler J., and Rowley D.R. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin. Cancer Res. 9 13 (2003) 4792-4801
48. Mydlo J.H., Kral J.G., Volpe M., Axotis C., Macchia R.J., and Pertschuk L.P. An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications. Eur. Urol. 34 5 (1998) 426-432
49. Mohler J.L., Chen Y., Hamil K., Hall S.H., Cidlowski J.A., Wilson E.M., French F.S., and Sar M. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin. Cancer Res. 2 5 (1996) 889-895
50. Sadi M.V., Walsh P.C., and Barrack E.R. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67 12 (1991) 3057-3064
51. Mirkin S.M. Expandable DNA repeats and human disease. Nature 447 7147 (2007) 932-940
52. de Vere White R., Meyers F., Chi S.G., Chamberlain S., Siders D., Lee F., Stewart S., and Gumerlock P.H. Human androgen receptor expression in prostate cancer following androgen ablation. Eur. Urol. 31 1 (1997) 1-6